Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Human Leukocyte Antigen (HLA) Typing For Oncology Immunotherapy Market Expansion Outlook: What Revenue Opportunities Are Ahead?
The human leukocyte antigen (HLA) typing for oncology immunotherapy market size has experienced significant expansion in recent years. This market is anticipated to expand from $1.22 billion in 2025 to $1.31 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.8%. Factors contributing to its growth in the past include the increasing global incidence of cancer, advancements in PCR and sequencing technologies, the growing embrace of precision oncology strategies, an uptick in clinical research for immunotherapies, and the broader application of biomarker-driven treatment selection.
The human leukocyte antigen (HLA) typing for oncology immunotherapy market is projected to experience robust expansion over the coming years. This market is forecast to reach $1.79 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.0%. This anticipated growth is driven by factors such as an expanding pipeline of cell and gene therapies, increased investment in personalized immunotherapy research, a growing need for companion diagnostics, the global expansion of oncology clinical trials, and enhanced regulatory backing for precision medicine. Key trends anticipated during this period encompass the wider adoption of next-generation sequencing-based HLA typing, greater integration of HLA profiling into adoptive T-cell therapies, increased utilization of high-resolution HLA typing in clinical trials, the proliferation of personalized cancer vaccine development, and an intensified focus on predictive immune compatibility testing.
Get A Free Sample Report With In-Depth Market Insights:
Human Leukocyte Antigen (HLA) Typing For Oncology Immunotherapy Market Industry Drivers: What’s Behind The Revenue Growth?
The increasing adoption of personalized medicine is anticipated to propel the expansion of the human leukocyte antigen (HLA) typing for oncology immunotherapy market. Personalized medicine involves customizing medical treatments and healthcare decisions based on an individual’s unique genetic, molecular, and clinical characteristics, aiming for more precise and effective therapies. Its rise is primarily attributed to advancements in genomics, which enable clinicians to identify specific genetic variations influencing disease risk and drug responses, leading to more targeted and impactful treatments. Human leukocyte antigen typing is instrumental in personalized oncology immunotherapy by determining a patient’s distinct immune profile, thereby allowing for tailored treatments that optimize tumor antigen recognition and immune response. For example, the US-based nonprofit Personalized Medicine Coalition reported in February 2024 that the FDA approved 16 new personalized treatments for rare disease patients in 2023, a notable increase from 6 in 2022. The 2023 approvals further included 7 cancer drugs and 3 for other diseases and conditions. This growing embrace of personalized medicine is thus a significant factor driving the growth of the human leukocyte antigen (HLA) typing for oncology immunotherapy market.
Human Leukocyte Antigen (HLA) Typing For Oncology Immunotherapy Market Segment Analysis And Revenue Potential
The human leukocyte antigen (HLA) typing for oncology immunotherapy market covered in this report is segmented –
1) By Technology: Polymerase Chain Reaction (PCR)-Based, Sequencing-Based, Sequence-Specific Oligonucleotide (SSO), Sequence-Specific Primer (SSP), Other Technologies
2) By Product Type: Reagents And Kits, Instruments, Software
3) By Application: Cancer Diagnosis, Personalized Medicine, Research, Clinical Trials, Other Applications
4) By End-User: Hospitals And Diagnostic Laboratories, Research Institutes, Academic Centers, Pharmaceutical And Biotechnology Companies, Other End-Users
Subsegments:
1) By Polymerase Chain Reaction Based: Real Time Polymerase Chain Reaction, Nested Polymerase Chain Reaction, Multiplex Polymerase Chain Reaction, Digital Polymerase Chain Reaction
2) By Sequencing Based: Next Generation Sequencing, Sanger Sequencing, Whole Genome Sequencing, Targeted Gene Sequencing
3) By Sequence Specific Oligonucleotide: Luminex Based Sequence Specific Oligonucleotide, Microarray Based Sequence Specific Oligonucleotide, Bead Based Sequence Specific Oligonucleotide, Plate Based Sequence Specific Oligonucleotide
4) By Sequence Specific Primer: Conventional Sequence Specific Primer, Multiplex Sequence Specific Primer, Real Time Sequence Specific Primer, Nested Sequence Specific Primer
5) By Other Technologies: Flow Cytometry Based Typing, Mass Spectrometry Based Typing, Immunoassay Based Typing, Hybridization Based Typing
#Human Leukocyte Antigen (HLA) Typing For Oncology Immunotherapy Market Growth Trends: What’s Shaping The Future Outlook?
Major companies within the human leukocyte antigen (HLA) typing for oncology immunotherapy market are concentrating on developing innovative solutions, such as allele-specific patient selection, to enhance personalized immunotherapy efficacy and improve clinical outcomes. Allele-specific patient selection involves identifying patients based on their specific HLA gene variants to tailor immunotherapy for optimal effectiveness. For instance, in August 2024, Thermo Fisher Scientific Inc., a US-based biotechnology company, received approval from the FDA for the SeCore HLA typing kit for use as a companion diagnostic with a T-cell receptor therapy for synovial sarcoma. This approval significantly expands HLA sequencing from transplant diagnostics into oncology immunotherapy by enabling precise patient selection for TCR-based treatments targeting tumor antigens.
Human Leukocyte Antigen (HLA) Typing For Oncology Immunotherapy Market Key Players Shaping Industry Direction
Major companies operating in the human leukocyte antigen (HLA) typing for oncology immunotherapy market are Thermo Fisher Scientific Inc., Danaher Corporation, Becton, Dickinson Company, Eurofins Scientific SE, Illumina Inc., Werfen, QIAGEN N.V., Versiti Inc., CareDx Inc., Oxford Nanopore Technologies Plc., Pacific Biosciences of California Inc., Takara Bio Inc., HistoGenetics LLC, Biofortuna Limited, Bio‑Rad Laboratories Inc., DKMS Life Science Lab, ClinImmune Inc., BGI Genomics Co. Ltd., Immudex A/S, ProImmune Ltd.
View The Full Human Leukocyte Antigen (HLA) Typing For Oncology Immunotherapy Market Report:
Human Leukocyte Antigen (HLA) Typing For Oncology Immunotherapy Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the human leukocyte antigen (HLA) typing for oncology immunotherapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human leukocyte antigen (HLA) typing for oncology immunotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

